307 related articles for article (PubMed ID: 29220430)
1. Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease.
Lightner AL; McKenna NP; Tse CS; Hyman N; Smith R; Ovsepyan G; Fleshner P; Crowell K; Koltun W; Ferrante M; D'Hoore A; Lauwers N; Verstockt B; Spinelli A; DiCandido F; Raffals LE; Mathis KL; Loftus EV
J Crohns Colitis; 2018 Mar; 12(4):402-407. PubMed ID: 29220430
[TBL] [Abstract][Full Text] [Related]
2. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients.
Lightner AL; McKenna NP; Alsughayer A; Loftus EV; Raffals LE; Faubion WA; Moir C
J Pediatr Surg; 2019 Oct; 54(10):2162-2165. PubMed ID: 30773391
[TBL] [Abstract][Full Text] [Related]
3. Hypoalbuminaemia, Not Biologic Exposure, Is Associated with Postoperative Complications in Crohn's Disease Patients Undergoing Ileocolic Resection.
Shah RS; Bachour S; Jia X; Holubar SD; Hull TL; Achkar JP; Philpott J; Qazi T; Rieder F; Cohen BL; Regueiro MD; Lightner AL; Click BH
J Crohns Colitis; 2021 Jul; 15(7):1142-1151. PubMed ID: 33388775
[TBL] [Abstract][Full Text] [Related]
4. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?
Lightner AL; McKenna NP; Alsughayer A; Harmsen WS; Taparra K; Parker ME; Raffals LE; Loftus EV
Dis Colon Rectum; 2019 Nov; 62(11):1352-1362. PubMed ID: 31567927
[TBL] [Abstract][Full Text] [Related]
5. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study.
Lightner AL; Mathis KL; Tse CS; Pemberton JH; Shen B; Kochhar G; Singh A; Dulai PS; Eisenstein S; Sandborn WJ; Parry L; Stringfield S; Hudesman D; Remzi F; Loftus EV
Inflamm Bowel Dis; 2018 Mar; 24(4):871-876. PubMed ID: 29509927
[TBL] [Abstract][Full Text] [Related]
6. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.
Lightner AL; Raffals LE; Mathis KL; Cima RR; Tse CS; Pemberton JH; Dozois EJ; Loftus EV
J Crohns Colitis; 2017 Feb; 11(2):185-190. PubMed ID: 27543504
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients.
Syed A; Cross RK; Flasar MH
Am J Gastroenterol; 2013 Apr; 108(4):583-93. PubMed ID: 23481144
[TBL] [Abstract][Full Text] [Related]
8. Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations.
Lightner AL; McKenna NP; Tse CS; Raffals LE; Loftus EV; Mathis KL
Aliment Pharmacol Ther; 2018 Mar; 47(5):573-580. PubMed ID: 29250800
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.
Chapuis-Biron C; Kirchgesner J; Pariente B; Bouhnik Y; Amiot A; Viennot S; Serrero M; Fumery M; Allez M; Siproudhis L; Buisson A; Pineton de Chambrun G; Abitbol V; Nancey S; Caillo L; Plastaras L; Savoye G; Chanteloup E; Simon M; Dib N; Rajca S; Amil M; Parmentier AL; Peyrin-Biroulet L; Vuitton L;
Am J Gastroenterol; 2020 Nov; 115(11):1812-1820. PubMed ID: 33156100
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
Biemans VBC; van der Woude CJ; Dijkstra G; van der Meulen-de Jong AE; Löwenberg M; de Boer NK; Oldenburg B; Srivastava N; Jansen JM; Bodelier AGL; West RL; de Vries AC; Haans JJL; de Jong D; Hoentjen F; Pierik MJ;
Aliment Pharmacol Ther; 2020 Jul; 52(1):123-134. PubMed ID: 32441396
[TBL] [Abstract][Full Text] [Related]
11. The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab.
Kassouri L; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
Dig Liver Dis; 2020 Oct; 52(10):1148-1155. PubMed ID: 32828693
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Anti-Tumor Necrosis Factor Alpha Therapy on Postoperative Complications in Pediatric Crohn's Disease.
Dotlacil V; Bronsky J; Hradsky O; Frybova B; Coufal S; Skaba R; Rygl M
Eur J Pediatr Surg; 2020 Feb; 30(1):27-32. PubMed ID: 31600799
[TBL] [Abstract][Full Text] [Related]
13. Early Postoperative Anti-TNF Therapy Does Not Increase Complications Following Abdominal Surgery in Crohn's Disease.
Schad CA; Haac BE; Cross RK; Syed A; Lonsako S; Bafford AC
Dig Dis Sci; 2019 Jul; 64(7):1959-1966. PubMed ID: 30684075
[TBL] [Abstract][Full Text] [Related]
14. Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease.
Lightner AL; Tse CS; Potter DD; Moir C
J Pediatr Surg; 2018 Sep; 53(9):1706-1709. PubMed ID: 29111083
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.
Wils P; Bouhnik Y; Michetti P; Flourie B; Brixi H; Bourrier A; Allez M; Duclos B; Grimaud JC; Buisson A; Amiot A; Fumery M; Roblin X; Peyrin-Biroulet L; Filippi J; Bouguen G; Abitbol V; Coffin B; Simon M; Laharie D; Pariente B;
Clin Gastroenterol Hepatol; 2016 Feb; 14(2):242-50.e1-2. PubMed ID: 26432476
[TBL] [Abstract][Full Text] [Related]
16. Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience.
Shwaartz C; Fields AC; Sobrero M; Cohen BD; Divino CM
J Gastrointest Surg; 2016 Sep; 20(9):1636-42. PubMed ID: 27405310
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review and Meta-Analysis: Association between Preoperative Ustekinumab and Surgical Complications in Crohn's Disease Patients.
Li L; Jiang K; Lou D; Zhang M; Shi Y; Shen J; Fu X
Eur Surg Res; 2023; 64(4):412-421. PubMed ID: 37598662
[TBL] [Abstract][Full Text] [Related]
18. Postoperative Safety Profile of Minimally Invasive Ileocolonic Resections for Crohn's Disease in the Era of Biologic Therapy.
Abd El Aziz MA; Abdalla S; Calini G; Saeed H; Stocchi L; Merchea A; Colibaseanu DT; Shawki S; Larson DW
J Crohns Colitis; 2022 Aug; 16(7):1079-1088. PubMed ID: 35045164
[TBL] [Abstract][Full Text] [Related]
19. The effect of immune therapy on surgical site infection following Crohn's Disease resection.
Serradori T; Germain A; Scherrer ML; Ayav C; Perez M; Romain B; Palot JP; Rohr S; Peyrin-Biroulet L; Bresler L
Br J Surg; 2013 Jul; 100(8):1089-93. PubMed ID: 23649458
[TBL] [Abstract][Full Text] [Related]
20. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
Liefferinckx C; Verstockt B; Gils A; Noman M; Van Kemseke C; Macken E; De Vos M; Van Moerkercke W; Rahier JF; Bossuyt P; Dutré J; Humblet E; Staessen D; Peeters H; Van Hootegem P; Louis E; Franchimont D; Baert F; Vermeire S;
J Crohns Colitis; 2019 Oct; 13(11):1401-1409. PubMed ID: 30989232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
